Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 07/01/23
End: 07/01/25
Due: 07/01/26
Phase: N/A
Priority: Normal
Start: 03/26/24
End: 03/26/26
Due: 03/26/27
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase IV Observational Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Cell Lymphoma | NCT05920668 | Wang Xin | user2@example.com | None | 2023-07-01 | 2025-07-01 | 2026-07-01 | - | - | 2025-07-14 |
| Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT | NCT06334367 | Wang Xin | user2@example.com | None | 2024-03-26 | 2026-03-26 | 2027-03-26 | - | - | 2025-07-14 |